Loading...
By Amy Orciari Herman
Edited by André Sofair, MD, MPH
A new study in The BMJ offers some reassurance about newer diabetes drugs and risk for pancreatic cancer. Another analysis, however, is less encouraging in terms of risk for heart failure admission.
In the first study, researchers used electronic medical record data from the U.S., the U.K., and Canada to examine the risk for pancreatic cancer in nearly 1 million patients starting antidiabetes drugs. During a median follow-up of roughly 1–3 years, some 1220 patients were diagnosed with pancreatic cancer. Neither dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., saxagliptin) nor glucagon-like peptide-1 receptor agonists (e.g., liraglutide) were associated with increased risk, relative to sulfonylureas.
The second study, a meta-analysis, included moderate-quality evidence from five placebo-controlled trials among diabetic patients with, or at high risk for, cardiovascular disease. During 1–3 years' follow-up, the rate of heart failure admission was higher with DPP-4 inhibitors — 3.4% vs. 3.0% — a difference of borderline statistical significance.
Comment
LINK(S):
BMJ article on pancreatic cancer (Free)
BMJ article on heart failure (Free)
BMJ editorial (Subscription required)
Background: NEJM Journal Watch General Medicine coverage of sitagliptin and cardiovascular risk (Free)